RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign

RepliCel Retains O&M Partners to Coordinate North American Focused Investor 
Marketing Campaign 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: RepliCel Life Sciences Inc. 
TSX VENTURE SYMBOL:  RP
OTCQB SYMBOL:  REPCF 
JUNE 20, 2014 
RepliCel Retains O&M Partners to Coordinate North American Focused Investor
Marketing Campaign 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 20, 2014) - RepliCel Life
Sciences Inc. (TSX VENTURE:RP)(OTCQB:REPCF), today announced that it has
retained O&M Partners, LLC to assist in targeting non-deal institutional
and independent money managers throughout the United States including financial
centres often overlooked by biotech companies. This marketing effort will
include a combination of group Town Hall conference calls and follow-up
roadshows. With the commencement of three human clinical trials before
year-end, management is dedicated to meeting as many non-deal investors as
possible. This campaign is an integral part of the company's overall
marketing effort focused on the United States. 
O&M Partners, LLC is internationally recognised by institutional and
independent money managers for its ability to discover high-potential
companies, identify sector trends, and qualify market sentiment. Since 1995,
O&M's New York-based marketing professionals have been bringing Wall
Street together with the senior management of publicly traded companies on the
TSX, AMEX and NASDAQ. O&M specializes in non-deal institutional marketing
of micro-and small-caps. 
About RepliCel Life Sciences  
RepliCel is a regenerative medicine company focused on developing autologous
cell therapies that address diseases caused by a deficit of healthy cells
required for normal healing and function such as chronic tendinosis, damaged
skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies
are designed to treat chronic tendinosis and damaged or aging skin
respectively, using fibroblasts isolated from the sheath of the hair follicle.
Another of the company's pipeline products, RCH-01 for the treatment of
pattern baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South Korea. All
product candidates are based on RepliCel's innovative technology which
utilizes cells isolated from a patient's own healthy hair follicles to
address specific cellular deficits. For additional information please visit
www.replicel.com.  
On Behalf of the Board  
RepliCel Life Sciences Inc. 
David Hall, President and Chief Executive Officer   
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
CORPORATE CONTACT:
RepliCel Life Sciences
Tammey George, Director of Communications
604-248-8696
tg@replicel.com
or
US INVESTOR RELATIONS:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
858-356-5932
robert.uhl@westwicke.com
or
CANADIAN INVESTOR RELATIONS:
Christina Cameron
christina@clcameron.com 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Trials 
SUBJECT:  BFC 
-0-
-0- Jun/20/2014 21:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.